Innovative BioDefense Inc. (IBD), manufacturer of the Zylast line of broad-spectrum, persistent antimicrobial products, announces an exclusive relationship with Australian-based Picketts Health, to provide a modification of their proprietary lotion and antiseptic sanitizer for use in Picketts Health's patented Orbel hand sanitizer applicator. IBD has delivered a pilot production batch and is currently fulfilling Picketts' first orders. Picketts Health has committed to the purchase of $1.5 million in product from IBD during the first year, with a projection to increase to $4 million in the second year.
The Orbel was designed to increase hand-hygiene compliance and help prevent the spread of bacteria and viruses. Portable, with single-handed activation of a regulated dose, the Orbel's multi-directional balls evenly facilitate distribution to all parts of the hands for increased protection.
The Zylast line of antimicrobial products is all natural, water-based and triclosan-free. Zylast has shown to kill 99.99 percent of most disease-causing germs in 15 seconds and is persistent for six hours. Independent studies have shown Zylast to be effective against a broad spectrum of germs that includes 25 bacteria such as E. coli, S. pneumoniae, meningitis, methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococci (VRE), viruses such as rhinovirus, norovirus, H1N1, HIV and herpes, as well as molds and fungi.
"We are pleased Picketts Health has taken an important step toward solving the issue of compliance with the introduction of the Orbel," says Dr. Colette Cozean, chief executive officer for Innovative BioDefense Inc. "Their choice in bringing Zylast in as the formulary shows their commitment to providing the premier antimicrobial solution." The first markets Picketts Health plans to target are the United Kingdom, South Africa, Australia and China. Zylast is protected by trademarks and patents pending in many countries worldwide.
Source: Innovative BioDefense Inc.